Projects
Universal chimeric antigen receptor (uniCAR)-T cell therapy to treat autoimmune diseases: immune mediated thrombotic thrombocytopenic purpura as a model system. KU Leuven
Long-term treatment of autoimmune disorders is still an unmet clinical need. In this project, we will develop an innovative therapy to realize long-term treatment of autoimmune disorders. The autoimmune disorder immune-mediated thrombotic thrombocytopenic purpura (iTTP) will serve as the disease model as the autoimmune response in iTTP is well known and autoantibodies are directed against only one antigen. As an innovative therapy, we will ...
RESPONSE PREDICTION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTORTARGETED THERAPY AND/OR IMMUNE CHECKPOINT INHIBITORS KU Leuven
During the last decade, two active therapeutic approaches have been developed for metastatic kidney cancer: angiogenesis inhibitors and immune checkpoint inhibitors. Both therapies can lead to prolonged disease control. In some cases, immune therapy can even lead to complete remissions. However, not all the patients will respond to one or the other therapy and in many cases, even after a first period of response, the disease will relapse. The ...
RESPONSE PREDICTION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TARGETED THERAPY AND/OR IMMUNE CHECKPOINT INHIBITORS KU Leuven
Development of a novel treatment strategy combining cell therapy with immune priming for paediatric high-grade gliomas. University of Antwerp
Development of a novel treatment strategy combining cell therapy with immune priming for paediatric high-grade gliomas. University of Antwerp
Blocking immune cell migration into the brain: a targeted therapy for autoimmune and neurodegenerative diseases Hasselt University
Quest for tissue biomarkers for immune therapy in non-small cell lung cancer KU Leuven
The research and quest for tissue biomarkers for immune therapy in non-small cell lung cancer. Defining immunological heterogeneity within tumours and correlate intra-tumour heterogeneity with response on immune treatment